Newsroom

UBP’s experts unveil their investment views for the upcoming year in the “Walking the tightrope” roadshow.

John Neppl, Chief Financial Officer of Bunge, an international leader in the agribusiness and food space, was invited to share his insights at UBP’s latest EXPERT SERIES webinar. This interactive session was hosted by Norman Villamin, CIO Wealth Management at UBP, and included Marc Elliott, Investment Specialist Energy Transition at UBP.

The investment landscape has changed substantially in the last six months: conflict has broken out in Ukraine, leading to various geopolitical and social ramifications, and inflationary pressure has been rising and remains a concern across many regions.

Finews (19.05.2022) - Financial markets are not about to return to the normality of past years, says Norman Villamin, CIO Wealth Management, to finews.ch.

Le Temps (20.04.2022) - The war in Ukraine has created a highly unusual environment for investors, writes Michaël Lok, Group Chief Investment Officer at UBP.

Finanz und Wirtschaft (17.01.2022) - Norman Villamin, CIO Wealth Management of Union Bancaire Privée, expects a radical shift in monetary policy. A tightening cycle is less bad for equities than for bonds and gold, he says.

In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.

Embracing Change

Volatility is back in Chinese equity markets: after rallying 90% from its trough in March 2020 to a peak in February 2021, MSCI China has fallen by 16% over the past month.

Finanz und Wirtschaft (19.01.2021) - Norman Villamin, Chief Investment Officer Wealth Management of Union Bancaire Privée, considers fears of significantly higher interest rates to be premature. He prefers mining to banking stocks.

Japan’s equity markets have outpaced other major developed market equities in both 2020 and year-to-date in 2021 as the world seeks to transition to a post-pandemic recovery.

UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.